The shares of Astex Pharmaceuticals (NASDAQ:ASTX) boosted nearly 37% last week, due to up grading of the company by TheStreet; the firm upgraded the company from “hold” to “buy.” And after three days the sale of the company shares start selling which continue to the end of the week.
Let’s have a short overview of the financial highlights of the stock, Shares of Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) increased 9.71% to settle at $4.52 on March 8, 2013.
ASTX has 149 employees. Sales of ASTX were 80.30 million with net income of 3.94 million.
ASTX stock surged during the trade to the maximum level at $4.58 and at the lowest level of $4.12 after opening price of $4.12. ASTX has earning per share of $0.08.
The price to sales ratio of ASTX in past twelve months was calculated as 5.26 and price to cash ratio remained 3.25. While retunes ratios are concerned, the ASTX return on equity ratio is recorded as 1.74% and increased 1.61% return on investment while its return on assets remain 1.44%.
TheStreet Ratings also upgraded Pacira Pharmaceuticals Inc (NASDAQ:PCRX) from sell to hold. The company has strengthen itself in multiple areas, such as revenue growth greatly exceeded the industry average of 8.4% which helped boost the earnings per share. While the present debt-to-equity ratio of the company is 0.40, is low and is below the industry average.
Coming to the stock performance in last Session; Pacira Pharmaceuticals Inc (NASDAQ:PCRX) in last trading session end up at $28.18 by rising up 7.97% with traded volume of 943,835 shares which is up the average volume of 363,587 shares.
The stock price saw week’s volatility of 5.93% and month’s volatility is 4.31%, while the stock price of the company is moving up from its 20 days moving average with 31.31% and isolated positively from 50 days moving average with 41.52%.
Looking at Analytic Ratios; the price to sales ratio of PCRX in past twelve months was calculated as 27.98 and price to cash ratio as 13.74.Company return on equity ratio is recorded as -108.60% and its return on assets is -48.68%.
A sharp increase in drug approvals Novogen Limited (ADR) (NASDAQ:NVGN) has approved by U.S. Food and Drug Administration. The company is focused on the development of anti-cancer drugs, base on’stealth’ drug and super-benzopyran technologies.
Novogen’s lead experimental drug candidate is CS-6. Shares of the Novogen were sent high earlier this month after the company report that CS-6 was “highly active” against ovarian cancer stem cells.
Let’s have a short overview of the financial highlights of the stock, Shares of Novogen Limited (ADR) (NASDAQ:NVGN) increased 6.01% to settle at $6.00 on March 8, 2013.
NVGN has 13employees. Sales of NVGN were 2.50 million with net income of -6.21 million.
NVGN stock surged during the trade to the maximum level at $6.35 and at the lowest level of $5.41 after opening price of $5.70. NVGN has earning per share of $-0.91 while it has 6.79 million shares outstanding with institutional ownership of 3%.
The price to sales ratio of NVGN in past twelve months was calculated as 11.28 and price to cash ratio remained 3.31. While retunes ratios are concerned, the NVGN return on equity ratio is recorded as -157.92% and decreased -223.72% return on investment while its return on asset remain -80.53%.